ursodiol (Rx)

>10%

Headache

Dizziness

Diarrhea

Dyspepsia

Nausea/vomiting

Back pain

Upper respiratory tract infection

1-10%

Alopecia

Rash

Hyperglycemia

Flatulence

Peptic ulcer

Urinary tract infection

Leukopenia

Thrombocytopenia

Cholecystitis

>1%

Fatigue

Abdominal pain

Thrombocytopenia

Pruritus

Angioedema

Peripheral edema

Biliary pain

Postmarketing Reports

Hepatobiliary disorders: Jaundice (or aggravation of pre-existing jaundice)

Abnormal laboratory tests: Increased ALT, AST, alkaline phosphatase, bilirubin, gamma-GT

Contraindications

Hypersensitivity

Gallstone complication requiring surgery

Known hepatocyte or bile ductal abnormalities, inflammatory bowel disease

Calcified gallstones, bile acid allergy, chronic hepatic disease

Billiary gastrointestinal fistula

Patients requiring cholecystectomy

Cautions

Only use in radiolucent, non calcified, high cholesterol content gallstone

Chronic liver disease

Liver function tests (gamma-GT, alkaline phosphatase, AST, ALT) and bilirubin levels should be monitored q3months x3 months after start of therapy, and q6months thereafter

Gallbladder stone dissolution may take several months

50% of cases have stone recurrence in 5 yr

Pregnancy Category: B

Lactation: unknown if excreted in breast milk; use caution

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Naturally-occurring bile acid; reduces cholesterol secretion from the liver; reduces the fractional reabsorption of cholesterol by the intestines.

Absorption

Bioavailability: 90%

Onset: Initial response for gallstone dissolution is 3-6 months

Distribution

Protein Bound: 70%

Metabolism

Taken up rapidly by the liver, conjugated with glycine or taurine, and excreted in the bile

Nonabsorbed ursodiol passes into the colon where it is 7-dehydroxylated to lithocholic acid (an intermediary compound, sometimes formed, is called chenodiol); chenodiol is then dehydroxylated to lithocholic acid

Metabolites: Glyco-ursodeoxycholic acid, tauro-ursodeoxycholic acid, 7-keto-lithocholic acid (inactive); lithocholic acid (inactive) is formed from the 7-hydroxylation of ursodiol and chenodiol; a small portion is metabolized to sulfated lithocholic acid conjugates which are excreted in bile & eliminated in feces

Elimination

Excretion: Mainly in feces